What is the global market size of Neurological Biomarkers Market?

Global Neurological Biomarkers Market size was valued at USD 5.4 Billion in 2021 and is poised to grow from USD 6.13 Billion in 2022 to USD 17.01 Billion by 2030, at a CAGR of 13.6% during the forecast period (2023-2030).

Who are the key vendors in the Global Neurological Biomarkers Market?

The global neurological biomarkers market features a competitive landscape characterised by a diverse array of players, including technology developers, diagnostic companies, research institutions, and pharmaceutical firms. The competition is driven by the increasing demand for reliable and accurate biomarkers to aid in the diagnosis and management of neurological disorders. The continuous evolution of biomarker research, technological advancements, and the identification of novel biomarkers will shape the competitive landscape, providing opportunities for companies to differentiate themselves and contribute to advancements in neurological care. 'Quanterix Corporation (US)', 'Thermo Fisher Scientific Inc. (US)', 'Myriad Genetics, Inc. (US)', 'QIAGEN N.V. (Germany)', 'Bio-Rad Laboratories, Inc. (US)', 'Merck KGaA (Germany)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Siemens Healthineers AG (Germany)', 'Johnson & Johnson (US)', 'Bio-Techne Corporation (US)', 'Alector Inc. (US)', 'Banyan Biomarkers, Inc. (US)'.

What is the key driver of Global Neurological Biomarkers Market?

The increasing prevalence of neurological disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and others, is a significant driver of the global neurological biomarkers market. As the incidence of these disorders continues to rise, there is a growing demand for accurate and early diagnostic tools to enable timely intervention and effective disease management.

What is the key market trend for Global Neurological Biomarkers Market?

Integration of Artificial Intelligence (AI) and Machine Learning (ML): The incorporation of AI and ML algorithms in biomarker research and data analysis gained prominence. These advanced technologies helped in automating data interpretation, identifying patterns, and predicting disease outcomes, enhancing the efficiency and accuracy of neurological biomarker discovery and validation.

Which region accounted for the largest share in Global Neurological Biomarkers Market?

North America stands as the dominant market for neurological biomarkers. North America's dominance can be attributed to the presence of well-established healthcare infrastructure, extensive research and development activities, and a high prevalence of neurological disorders in the region. Additionally, strong support from government and private organisations for innovative biomarker research and adoption further contributes to North America's leading position in the market.

Neurological Biomarkers Market Share, Size & Growth Report

Neurological Biomarkers Market Competitive Landscape

Neurological Biomarkers Market Top Player’s Company Profile

Quanterix Corporation

Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
QIAGEN N.V.
Bio-Rad Laboratories, Inc.
Merck KGaA
F. Hoffmann-La Roche Ltd
Bio-Techne Corporation
Alector Inc.
Banyan Biomarkers, Inc.
Charles River Laboratories International, Inc.
Cisbio
C2N Diagnostics
ImmunArray
Euroimmun AG
Cerebrospinal Fluid Diagnostics
Abbott Laboratories

Neurological Biomarkers Market

FAQs

Neurological Biomarkers Market size was valued at USD 6.13 Billion in 2022 and is poised to grow from USD 6.96 Billion in 2023 to USD 19.31 Billion by 2031, at a CAGR of 13.6% during the forecast period (2024-2031).

The neurological biomarkers industry is experiencing the presence of many renowned, small and mid-sized players. This companies are dynamically engaging in providing consumables, software and services related to biomarker. These stakeholders are actively taking strategic initiatives to maintain their competitive edge through partnerships, clinical trials and seeking for investment opportunities. Market competition happens to be the critical, as new players are entering into market with strong focus on technology advancements and investing large amount of dollars to have a stronger foothold in this space. 'Quanterix Corporation ', 'Thermo Fisher Scientific Inc. ', 'Myriad Genetics, Inc. ', 'QIAGEN N.V.', 'Bio-Rad Laboratories, Inc. ', 'Merck KGaA ', 'F. Hoffmann-La Roche Ltd ', 'Bio-Techne Corporation ', 'Alector Inc. ', 'Banyan Biomarkers, Inc. ', 'Charles River Laboratories International, Inc. ', 'Cisbio ', 'C2N Diagnostics ', 'ImmunArray ', 'Euroimmun AG ', 'Cerebrospinal Fluid Diagnostics ', 'Abbott Laboratories'

As biomarkers are important indicators of various health or disease traits. Cancer goes through a multistage carcinogenesis procedure involving multiple events from various molecular pathways, which makes its diagnosis, prognosis and therapy extremely complicated. Due to this complexity, a single marker is insufficient. In addition, each cancer type has its unique molecular profile. Identification of new biomarkers leads to the development of targeted therapies that target dysregulation in cancer. The increasing prevalence of cancer will, in turn, stimulate biomarker research and thereby boosting the growth of neurological biomarkers market.

Increasing Funds for Research: The rising presence of companies offering funds at several stages of research is boosting market growth. For example, the University of North Texas Health Science Center (HSC) was offered almost USD 45.5 million in funds from the National Institutes of Health (NIH). This fund will help in supporting research related to health disparities in Alzheimer's and brain aging. NIH is also offering additional funds for biomarkers research for the present study for Health and Aging Brain Among Latino Elders (HABLE). Therefore, this new trend is fueling market growth.

The largest piece in the global neurological biomarkers market share is held by North America. This growth is mainly due to the well-established healthcare and research infrastructure in the region. The United States and Canada houses major pharmaceutical and biotechnology companies which provides them a competitive advantage in the research & development for new neurological biomarkers. Moreover, the renowned medical device players involved in neurobiology are also contributing to the regional growth market. The market growth is also supported by the initiatives from government bodies providing grants and funding for different neuroscience projects. Various U.S. and Canadian universities and academic institutions are collaborating with industry to develop new biomarkers.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Neurological Biomarkers Market Competitive Landscape

Neurological Biomarkers Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Neurological Biomarkers Market Competitive Landscape

Neurological Biomarkers Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Neurological Biomarkers Market?

Who are the key vendors in the Neurological Biomarkers Market?

What is the key driver of Neurological Biomarkers Market?

What is the key market trend for Neurological Biomarkers Market?

Which region accounted for the largest share in Neurological Biomarkers Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300